Mallinckrodt-Sucampo Pharmaceuticals deal receives US antitrust approval
MLex Summary: Mallinckrodt and Sucampo Pharmaceuticals have received clearance from the US antitrust authority for their $1.2 billion deal. The companies said in a securities filing that the waiting period under...To view the full article, register now.
Already a subscriber? Click here to view full article